Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Polycystic Ovary Syndrome
|
363 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.020 | 1.000 | 2 | 2016 | 2019 | |||||
Glioma
|
353 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.030 | 1.000 | 3 | 2011 | 2018 | |||||
Squamous cell carcinoma of esophagus
|
329 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Malignant neoplasm of urinary bladder
|
316 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Carcinoma of bladder
|
309 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Chronic Lymphocytic Leukemia
|
291 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Renal Cell Carcinoma
|
288 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.020 | 0.500 | 2 | 2017 | 2017 | |||||
Cervix carcinoma
|
283 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Glioblastoma
|
281 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.020 | 1.000 | 2 | 2015 | 2018 | |||||
Bladder Neoplasm
|
281 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Colon Carcinoma
|
275 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Endometriosis
|
274 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1 | 2013 | 2013 | ||||||
cervical cancer
|
268 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Migraine Disorders
|
264 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Vitiligo
|
249 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Malignant tumor of cervix
|
245 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Behcet Syndrome
|
243 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2004 | 2004 | |||||
Gestational Diabetes
|
224 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Conventional (Clear Cell) Renal Cell Carcinoma
|
222 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.030 | 0.667 | 3 | 2014 | 2017 | |||||
Diabetic Retinopathy
|
213 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.040 | 0.750 | 4 | 2013 | 2017 | |||||
Mucocutaneous Lymph Node Syndrome
|
195 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2006 | 2006 | |||||
Glioblastoma Multiforme
|
186 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.020 | 1.000 | 2 | 2015 | 2018 | |||||
Malignant neoplasm of mouth
|
184 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Osteosarcoma
|
178 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Lip and Oral Cavity Carcinoma
|
172 | 0.542 | 0.840 | 6 | 43770613 | 5 prime UTR variant | C/G | snv | 0.68 | 0.010 | 1.000 | 1 | 2012 | 2012 |